Jazz Pharmaceuticals (JAZZ) Change in Account Payables (2010 - 2026)

Jazz Pharmaceuticals' Change in Account Payables history runs 17 years deep, the most recent figure standing at -$21.4 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 212.04% year-over-year to -$21.4 million; the TTM figure through Mar 2026 stood at -$649000.0 (down 103.48% YoY), while the FY2025 annual figure was $39.9 million, up 298.53% from the prior year.
• Change in Account Payables was -$21.4 million for Q1 2026 at Jazz Pharmaceuticals, up from -$29.0 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $62.4 million in Q3 2025 to a low of -$29.0 million in Q4 2025.
• Historically, Change in Account Payables has averaged -$190823.5 across 5 years, with a median of -$8.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Change in Account Payables soared 20493.66% in 2022, then tumbled 1042.52% in 2023.
• A 5-year view of Change in Account Payables shows it stood at -$15.4 million in 2022, then surged by 47.43% to -$8.1 million in 2023, then jumped by 61.31% to -$3.1 million in 2024, then tumbled by 824.15% to -$29.0 million in 2025, then rose by 26.14% to -$21.4 million in 2026.
• The last three Change in Account Payables figures came in at -$21.4 million (Q1 2026), -$29.0 million (Q4 2025), and $62.4 million (Q3 2025), per Business Quant data.